Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
55 Leser
Artikel bewerten:
(0)

CareFusion Names James F. Hinrichs Chief Financial Officer / Key financial leader through spinoff from Cardinal Health promoted to top post, replacing Edward Borkowski

SAN DIEGO, Dec. 1, 2010 /PRNewswire-FirstCall/ -- CareFusion Corp. , a leading, global medical device company, announced today that James F. Hinrichs has been promoted to chief financial officer, replacing Edward Borkowski who will leave the company at the end of the month.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

As the former CFO of Cardinal Health's Clinical and Medical Products segment, Hinrichs, 43, led the CareFusion financial organization prior to the hiring of Borkowski in May 2009 and continued as controller until he was named senior vice president of Global Customer Support in January. The Cardinal Health Clinical and Medical Products segment became the foundation of CareFusion following its spinoff on Sept. 1, 2009.

"Jim is a seasoned leader that helped guide us through the spinoff and served as our external financial voice prior to Ed joining the company," said David L. Schlotterbeck, chairman and CEO of CareFusion. "He is already known by many of our investors and analysts, and has strong support from his new team and our board.

"I also want to thank Ed for the leadership he brought to CareFusion during an important time leading up to the spinoff and during our first year as a public company. My retirement plans and a decision made by our board to pursue candidates other than Ed for my replacement prompted his departure and Jim's promotion."

The company announced plans for Schlotterbeck's retirement on Nov. 2. He will continue in his role until Feb. 28, 2011, by which time the board intends to name a successor.

"Following Dave's decision to retire and the board's decision to pursue other candidates for his replacement, the timing is right for me to transition from CareFusion," said Borkowski. "I want to thank Dave and the employees of CareFusion for their support as we launched the company and set ourselves on a path for growth."

Prior to his role as CFO of the Clinical and Medical Products segment of Cardinal Health, Hinrichs served as executive vice president and controller of Cardinal Health and the CFO of Cardinal Health's Healthcare Supply Chain Services segment, at the time a multinational business generating annual revenues in excess of $80 billion. He joined Cardinal Health in February 2004 following 12 years of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in Business from Carnegie Mellon University.

About CareFusion Corporation

CareFusion is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AirLife(TM), AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined(TM) services for infection surveillance, V. Mueller® and Snowden-Pencer® surgical instruments and NeuroCare diagnostic products. CareFusion employs more than 15,000 people across its global operations. More information may be found at http://www.carefusion.com/.

Photo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO
PRN Photo Desk, photodesk@prnewswire.com

CareFusion Corp.

CONTACT: Media, Jim Mazzola, +1-858-617-1203,
jim.mazzola@carefusion.com, or Investors, Carol Cox, +1-858-617-2020,
carol.cox@carefusion.com, both of CareFusion Corp.

Web Site: http://www.carefusion.com/

© 2010 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.